“…A variety of functional defects, including altered Ca 2+ sensitivity and/or affinity, myofibrillar ATPase activity, Ca 2+ handling, cross-bridge dynamics, impaired energetics, oxidative stress and electrophysiologic abnormalities have been identified in experimental models (Straceski et al, 1994; Spindler et al, 1998; Blanchard et al, 1999; Gao et al, 1999; Georgakopoulos et al, 1999; Tardiff et al, 1999; Solaro et al, 2002; Javadpour et al, 2003; Adhikari et al, 2004; Szczesna-Cordary et al, 2004; Ertz-Berger et al, 2005; Hernandez et al, 2005; Robinson et al, 2007; Greenberg et al, 2009, 2010; Guinto et al, 2009; Mettikolla et al, 2011; Puglisi et al, 2014) and patients (Haq et al, 2001; Crilley et al, 2003; Nakamura et al, 2005; Dimitrow et al, 2009; Unno et al, 2009; Ho et al, 2010; Bravo et al, 2012; Coppini et al, 2013; Lin et al, 2013; Gruner et al, 2014). Since HCM-causing mutations increase the energetic cost of tension development, it has been hypothesized that excessive sarcomeric energy use leads to the HCM phenotype (Blair et al, 2001; Crilley et al, 2003; Abozguia et al, 2010).…”